Emergence of lymphomatoid papulosis during treatment with brentuximab vedotin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emergence of lymphomatoid papulosis during treatment with brentuximab vedotin

Published:2020-06-23 Issue:9 Volume:59 Page:
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatol

Author:

Mansoor Nazish¹,McKenna Laura²,Molloy Oonagh¹,Smyth Elizabeth³,Flavin Richard⁴,Ryan Cliona²,Quinn John³⁵,Roche Muireann¹

Affiliation:

1. Department of Dermatology Beaumont Hospital Dublin Ireland

2. Department of Histopathology Beaumont Hospital Dublin Ireland

3. Department of Haematology Beaumont Hospital Dublin Ireland

4. Department of Histopathology St James’ Hospital Dublin Ireland

5. School of Medicine Royal College of Surgeons in Ireland Dublin Ireland

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.15009

Reference9 articles.

1. Lymphomatoid Papulosis

2. National Cancer Institute.FDA approval for brentuximab vedotin.2016.http://www.cancer.gov/about‐cancer/treatment/drugs/fda‐brentuximabvedotin

3. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis

4. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders

5. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pityriasis lichenoides et varioliformis acuta-like eruption after brentuximab vedotin treatment for peripheral T-cell lymphoma;European Journal of Dermatology;2023-06

2. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies;Archives of Pathology & Laboratory Medicine;2022-03-17

3. Brentuximab vedotin;Reactions Weekly;2020-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3